Cocrystal Pharma, Inc.SEC Filings
|
|
All SEC filings by Cocrystal Pharma, Inc. (COCP) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 13, 2026 | |
| 10-Q | Quarterly report | View Diff | May 15, 2026 | |
| 10-K | Annual report | View Diff | Mar 31, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 14, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 14, 2025 | |
| 10-Q | Quarterly report | View Diff | May 15, 2025 | |
| 10-K | Annual report | View Diff | Mar 31, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 13, 2024 | |
| 10-Q | Quarterly report | View Diff | Aug 14, 2024 | |
| 10-Q | Quarterly report | View Diff | May 13, 2024 |
Events
| 8-K | Current report | Aug 18, 2026 | ||
| 8-K | Cocrystal Pharma Appoints Carol Brosgart, Md to Its Board of Directors | Aug 17, 2026 | ||
| 8-K | Cocrystal Pharma Announces $5 Million Private Placement with Opko Health | Aug 3, 2026 | ||
| 8-K | Current report | Jul 17, 2026 | ||
| 8-K | Current report | Jun 9, 2026 | ||
| 8-K | Current report | Jun 3, 2026 | ||
| 8-K | Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors | May 26, 2026 | ||
| 8-K | Regulation Fd Disclosure | Apr 30, 2026 | ||
| 8-K | Cocrystal Pharma Receives Fda Fast Track Designation for Cdi-988 for Norovirus Infection Treatment and Preventive | Apr 2, 2026 | ||
| 8-K | Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on Its Antiviral Drug-Development Programs | Mar 31, 2026 |
Registrations and Prospectuses
| S-3 | Shelf registration | View Diff | Apr 23, 2026 | |
| 424B3 | Prospectus supplement | Sep 29, 2025 | ||
| S-1 | IPO registration | Sep 19, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Sep 15, 2025 | ||
| 424B3 | Prospectus supplement | Sep 12, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Jun 15, 2023 | ||
| S-3/A | Shelf registration | View Diff | May 24, 2023 | |
| S-3 | Shelf registration | May 12, 2023 | ||
| 424B5 | Prospectus supplement for primary offering | May 5, 2021 | ||
| 424B5 | Prospectus supplement for primary offering | Aug 27, 2020 |
Proxies
| DEFA14A | Additional proxy soliciting materials | May 27, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | May 27, 2026 | |
| DEFA14A | Additional proxy soliciting materials | May 5, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | May 5, 2025 | |
| PRE 14A | Preliminary proxy | View Diff | Apr 25, 2025 | |
| DEF 14A | Definitive proxy | View Diff | May 7, 2024 | |
| PRE 14A | Preliminary proxy | View Diff | Apr 26, 2024 | |
| DEF 14A | Definitive proxy | View Diff | Apr 28, 2023 | |
| DEF 14A | Definitive proxy | View Diff | Apr 11, 2022 | |
| PRE 14A | Preliminary proxy | View Diff | Apr 1, 2022 |
Other
| EFFECT | Notice of effectiveness | May 4, 2026 | ||
| EFFECT | Notice of effectiveness | Sep 26, 2025 | ||
| CORRESP | Correspondence with SEC | Sep 25, 2025 | ||
| UPLOAD | Letter from SEC | Sep 24, 2025 | ||
| UPLOAD | Letter from SEC | Aug 28, 2025 | ||
| CORRESP | Correspondence with SEC | Aug 13, 2025 | ||
| UPLOAD | Letter from SEC | Jul 30, 2025 | ||
| EFFECT | Notice of effectiveness | May 30, 2023 | ||
| CORRESP | Correspondence with SEC | May 24, 2023 | ||
| UPLOAD | Letter from SEC | May 19, 2023 |
Ownership
| 3 | Brosgart Carol L | Aug 21, 2026 | ||
| SC 13D | Beneficial ownership report | Aug 7, 2026 | ||
| SC 13D/A | Beneficial ownership report | Aug 7, 2026 | ||
| 4 | Frost Phillip Md Et Al | Aug 6, 2026 | ||
| 4 | Frost Phillip Md Et Al | Aug 5, 2026 | ||
| 4 | Sapirstein James | Jun 3, 2026 | ||
| 3 | Sapirstein James | Jun 3, 2026 | ||
| 4 | Phillip Md Et Al Frost | Feb 25, 2026 | ||
| 4 | Phillip Md Et Al Frost | Feb 9, 2026 | ||
| 4 | Roger D. Kornberg | Jan 13, 2026 |